SSTR5 and benign neoplasm: Even though HTL0030310 structure is still undisclosed, Sosei Heptares designed this peptide as a selective SSTR5 (somatostatin 5) receptor agonist to treat endocrine disorders (Sosei Heptares, 2019) modulating the excess release of hormones from adenomas (benign tumors) of the pituitary gland.